| P50 | author | Inhee Mook-Jung | Q91432207 |
| P2093 | author name string | Yoonhee Kim | |
| | Hye Young Jang | |
| | Chaeyoung Kim | |
| P2860 | cites work | Cholesterol, lipid rafts, and disease | Q24553188 |
| | Statin adverse effects : a review of the literature and evidence for a mitochondrial mechanism | Q24603957 |
| | Regulated accumulation of desmosterol integrates macrophage lipid metabolism and inflammatory responses | Q24631052 |
| | Amyloidogenic processing of the Alzheimer beta-amyloid precursor protein depends on lipid rafts | Q24675729 |
| | The Fluid-Mosaic Model of Membrane Structure: still relevant to understanding the structure, function and dynamics of biological membranes after more than 40 years | Q26828455 |
| | The Amyloid Precursor Protein Has a Flexible Transmembrane Domain and Binds Cholesterol | Q27679405 |
| | Functional rafts in cell membranes | Q27860768 |
| | Serum total cholesterol, apolipoprotein E epsilon 4 allele, and Alzheimer's disease | Q28268162 |
| | Regulation of the mevalonate pathway | Q29547763 |
| | Amyloid-β and tau: the trigger and bullet in Alzheimer disease pathogenesis | Q30457367 |
| | Hypercholesterolemia accelerates the Alzheimer's amyloid pathology in a transgenic mouse model | Q33915820 |
| | Decreased prevalence of Alzheimer disease associated with 3-hydroxy-3-methyglutaryl coenzyme A reductase inhibitors. | Q33921362 |
| | The intersection of amyloid beta and tau at synapses in Alzheimer's disease | Q34054680 |
| | Safety profiles for the HMG-CoA reductase inhibitors: treatment and trust | Q34196622 |
| | FRET imaging | Q34274048 |
| | Statins and the risk of dementia | Q34511970 |
| | Simvastatin strongly reduces levels of Alzheimer's disease beta -amyloid peptides Abeta 42 and Abeta 40 in vitro and in vivo | Q34514599 |
| | Linking lipids to Alzheimer's disease: cholesterol and beyond | Q35875480 |
| | Isoprenoids: remarkable diversity of form and function | Q35882448 |
| | Is hypercholesterolemia a risk factor for Alzheimer's disease? | Q36161848 |
| | Defects of cholesterol biosynthesis | Q36550790 |
| | Mechanisms for cellular cholesterol transport: defects and human disease | Q36610465 |
| | The SPFH domain-containing proteins: more than lipid raft markers | Q36927166 |
| | Cholesterol and statins in Alzheimer's disease: current controversies | Q37603783 |
| | Membrane rafts in Alzheimer's disease beta-amyloid production | Q37715176 |
| | Direct binding of cholesterol to the amyloid precursor protein: An important interaction in lipid-Alzheimer's disease relationships? | Q37715389 |
| | Amyloid precursor protein processing and Alzheimer's disease | Q37860317 |
| | The link between altered cholesterol metabolism and Alzheimer's disease. | Q38023563 |
| | Neurotoxicity of amyloid β-protein: synaptic and network dysfunction | Q38023860 |
| | Role of cholesterol in APP metabolism and its significance in Alzheimer's disease pathogenesis | Q38043975 |
| | Statins in the prevention of dementia and Alzheimer's disease: a meta-analysis of observational studies and an assessment of confounding | Q38066159 |
| | Alzheimer's disease, cholesterol, and statins: the junctions of important metabolic pathways | Q38071004 |
| | Alzheimer's disease genetics: from the bench to the clinic | Q38225911 |
| | Structure of genes encoding steroidogenic enzymes | Q39687043 |
| | Targeting ADAM10 to lipid rafts in neuroblastoma SH-SY5Y cells impairs amyloidogenic processing of the amyloid precursor protein | Q39813034 |
| | Active gamma-secretase is localized to detergent-resistant membranes in human brain | Q40014328 |
| | Statins reduce amyloid-beta production through inhibition of protein isoprenylation | Q40103529 |
| | BACE1 interacts with lipid raft proteins | Q40258421 |
| | APP substitutions V715F and L720P alter PS1 conformation and differentially affect Abeta and AICD generation | Q40387366 |
| | Cellular cholesterol efflux mediated by cyclodextrins. Demonstration Of kinetic pools and mechanism of efflux. | Q41186178 |
| | Common statin side effects explain poor compliance | Q42332407 |
| | Direct and potent regulation of gamma-secretase by its lipid microenvironment | Q42347726 |
| | Cholesterol-dependent gamma-secretase activity in buoyant cholesterol-rich membrane microdomains | Q43889089 |
| | Statin therapy for Alzheimer's disease: will it work? | Q44125950 |
| | Statin effects on cholesterol micro-domains in brain plasma membranes | Q44356716 |
| | Gamma-secretase activity is present in rafts but is not cholesterol-dependent | Q44667739 |
| | DNA damage-inducing agents elicit gamma-secretase activation mediated by oxidative stress | Q46637801 |
| | A detergent-insoluble membrane compartment contains A beta in vivo | Q47982783 |
| | Local cholesterol increase triggers amyloid precursor protein-Bace1 clustering in lipid rafts and rapid endocytosis. | Q50528123 |
| | Defective cholesterol biosynthesis in Smith-Lemli-Opitz syndrome | Q52224994 |
| P433 | issue | 4 | |
| P304 | page(s) | 1057-1068 | |
| P577 | publication date | 2016-02-20 | |
| P1433 | published in | Journal of Alzheimer's Disease | Q6294755 |
| P1476 | title | Inhibition of Cholesterol Biosynthesis Reduces γ-Secretase Activity and Amyloid-β Generation | |
| P478 | volume | 51 | |